Literature DB >> 2415373

The antiproliferative effect of interferon and the mitogenic activity of growth factors are independent cell cycle events. Studies with vascular smooth muscle cells and endothelial cells.

A D Heyns, A Eldor, I Vlodavsky, N Kaiser, R Fridman, A Panet.   

Abstract

We studied the antagonistic effects of interferon (IFN) and growth factors in G0/G1-arrested normal bovine aortic smooth muscle cells (SMC) which were stimulated by serum, or purified platelet derived growth factor (PDGF), supplemented with plasma-derived serum (PDS). The growth response, measured as [3H]thymidine incorporation into DNA, was dependent on the concentration of the mitogen. Human IFN alpha, recombinant human IFN alpha 2, or a crude bovine-IFN preparation prepared from virus-infected bovine aortic endothelial cells, inhibited SMC growth induced by either serum or PDGF with PDS. The extent of IFN inhibition was inversely related to the concentration of the mitogenic stimulus. We also investigated whether IFN inhibited the early events in G1 phase, stimulated by the competence factor PDGF, or the progression of the cell into the S phase induced by PDS. The results indicated that IFN inhibited these two stages of the G1 phase independently. In addition, we investigated the antiproliferative effect of IFN on bovine aortic endothelial cells (BAEC), which do not respond to PDGF but to the mitogenic activity of fibroblast growth factor (FGF). IFN inhibited the mitogenic activity of FGF in a dose-dependent manner. The results indicate that the anti-proliferative activity of IFN and the mitogenic effects of different growth factors are independent.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2415373     DOI: 10.1016/0014-4827(85)90087-4

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  17 in total

Review 1.  The cellular receptor of the alpha-beta interferons.

Authors:  K E Mogensen; G Uzé; P Eid
Journal:  Experientia       Date:  1989-06-15

2.  Inhibition of vascular smooth muscle cell proliferation and intimal hyperplasia by gene transfer of beta-interferon.

Authors:  D Stephan; H San; Z Y Yang; D Gordon; S Goelz; G J Nabel; E G Nabel
Journal:  Mol Med       Date:  1997-09       Impact factor: 6.354

3.  Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo.

Authors:  M Fràter-Schröder; W Risau; R Hallmann; P Gautschi; P Böhlen
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

4.  Interferon alfa-2a in the treatment of exudative age-related macular degeneration.

Authors:  M L Lewis; J Davis; E Chuang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-11       Impact factor: 3.117

5.  Heparin inhibits c-fos and c-myc mRNA expression in vascular smooth muscle cells.

Authors:  L A Pukac; J J Castellot; T C Wright; B L Caleb; M J Karnovsky
Journal:  Cell Regul       Date:  1990-04

6.  Mechanism of anti-proliferation caused by YC-1, an indazole derivative, in cultured rat A10 vascular smooth-muscle cells.

Authors:  S M Yu; Z J Cheng; J H Guh; F Y Lee; S C Kuo
Journal:  Biochem J       Date:  1995-03-15       Impact factor: 3.857

7.  Antifibrotic and uveitogenic properties of gamma interferon in the rabbit eye.

Authors:  L M Hjelmeland; J W Li; C A Toth; M B Landers
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

8.  Effects of interferon-gamma on primary cultures of human brain microvessel endothelial cells.

Authors:  H K Huynh; K Dorovini-Zis
Journal:  Am J Pathol       Date:  1993-04       Impact factor: 4.307

9.  Immune interferon inhibits proliferation and induces 2'-5'-oligoadenylate synthetase gene expression in human vascular smooth muscle cells.

Authors:  S J Warner; G B Friedman; P Libby
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

10.  Purification of platelet-derived endothelial cell growth inhibitor and its characterization as transforming growth factor-beta type 1.

Authors:  S Magyar-Lehmann; P Böhlen
Journal:  Experientia       Date:  1992-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.